Clinical Trials
66
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (66 trials with phase data)• Click on a phase to view related trials
NG2 and DLL3 CAR-T Cells Targeting Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: NG2 and DLL3 CAR-T cells
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 100
- Registration Number
- NCT07193966
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
DLL3 CAR-T Therapy Targeting Brain Tumors
- Conditions
- Glioblastoma of Cerebellum
- Interventions
- Biological: 4SCAR DLL3 T cells
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT07180927
- Locations
- 🇨🇳
Shenzhen Geno-immuno Medical Institute, Shenzhen, Guangdong, China
Prostate Cancer Vaccines
- Conditions
- Prostate Cancer Indications
- Interventions
- Biological: Immunomodulatory DC vaccines to target prostate cancer
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT07068555
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
- Conditions
- Metachromatic Leukodystrophy (MLD)
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 10
- Registration Number
- NCT07046338
- Locations
- 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
Combination Immunotherapy Targeting Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Antigen-specific CAR T, CTL and DCvac to treat melanoma.
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06739226
- Locations
- 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
Dual-Target CAR-T Therapy Shows Promise for Glioblastoma with 24.5-Month Median Survival
A clinical trial combining PSMA and GD2 CAR-T cells achieved a median overall survival of 24.5 months in six patients with refractory or relapsed gliomas, significantly exceeding typical survival rates of 5-7 months.